Primary Mucinous Adenocarcinoma of the Vermiform Appendix with High Grade Microsatellite Instability by Komm, Moritz et al.
Journal of Cancer 2011, 2 
 
 
http://www.jcancer.org 
302 
J Jo ou ur rn na al l   o of f   C Ca an nc ce er r   
2011; 2:302-306 
Case Report 
Primary Mucinous Adenocarcinoma of the Vermiform Appendix with High 
Grade Microsatellite Instability 
Moritz Komm1, Michaela Kronawitter-Fesl2, Marcus Kremer2, Ludwig Lutz3, Elke Holinski-Feder4,    
Reinhard Kopp1  
1.  Department of General Surgery, Klinikum München-Harlaching, Munich, Germany  
2.  Department of Pathology, Klinikum München-Harlaching, Munich, Germany 
3.  Department of Haematology and Oncology, Klinikum München-Harlaching, Munich, Germany 
4.  Medical Genetic Center, Munich, Germany  
 Corresponding author: Moritz Komm, M.D., Klinik für Allgemein-, Viszeral-, Gefäß- und Thoraxchirurgie, Städtisches 
Klinikum München-Harlaching, Sanatoriumsplatz 2, 81545 München, Germany, e-mail: moritz@dr-komm.de, Phone: +49 89 
6210 2302 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2010.12.18; Accepted: 2011.05.13; Published: 2011.05.23 
Abstract 
Primary adenocarcinoma of the vermiform appendix is a rare entity and is frequently 
discovered by the pathologist following appendectomy for suspected appendicitis.  
We present a 42-year-old male with primary mucinous adenocarcinoma of the appendix 
initially  presenting  symptoms  of  acute  appendicitis.  Histological  investigation  of  the 
appendectomy  specimen  showed  a  mucinous  adenocarcinoma  and  the  patient  was 
treated by secondary right hemicolectomy giving the final histopathological classification 
of an UICC IIIC tumor. Since the patient fulfills the revised Bethesda criteria analysis of 
immunoreactivity  of  DNA  mismatch repair  proteins  was  performed  showing  loss  of 
MLH1 and MSH2 expression associated with high microsatellite instability (MSI-H), not 
yet reported for primary mucinous appendiceal carcinoma. Further genetic analysis for 
DNA mismatch repair gene mutations were negative. The patient received intensified 
adjuvant chemotherapy according to the FOLFOX-4-scheme, since MSI-H colorectal car-
cinomas  might  show  lower  response  rates  following  standard  5-FU-based  adjuvant 
chemotherapy. 
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Introduction 
Primary adenocarcinoma of the vermiform ap-
pendix is a rare entity and is frequently discovered by 
the  pathologist  following  appendectomy  for  sus-
pected appendicitis. Neoplasms of the appendix are 
found  in  1%  of  all  appendectomy  specimen  with  a 
frequency of appendiceal adenocarcinoma in 0,1% of 
the specimen investigated. The incidence of that type 
of neoplasm varies from 0,01 to 0,2 per 100.000 per-
sons per year (1) and it constitutes less than 0,5 % of 
all gastrointestinal malignant neoplasms (2, 3, 4).  
Case report 
We present a 42 year old male with mucinous 
adenocarcinoma  of  the  appendix  who  initially  pre-
sented with typical symptoms of acute appendicitis. 
Furthermore  the  patient  reported  recurrent  peranal 
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loss of blood, which was suspected to be associated 
with a history of colitis ulcerosa, known since 1997 
and continuously treated by NSAID.  
The  patient  was  treated  by  an  uncomplicated 
laparoscopic  appendectomy.  The  histopathological 
examination of the specimen surprisingly revealed a 
pT4a  (local  infiltration  of  the  visceral  peritoneum) 
mucinous adenocarcinoma of the appendix (figure 1) 
with positive resection margins (R1 resection). Staging 
examinations  including  colonoscopy,  gastroscopy, 
thoracical  x-ray  and  abdominal  ultrasound  were 
normal. Therefore, right hemicolectomy according to 
the  principals  of  oncologic  surgery  was  performed. 
The final histopathological classification described a 
pT4a, pN2 (6/15), L1, V0, M0, G3, R0 tumor, corre-
sponding to UICC IIIC classification.  
 
 
 
Figure 1: Haematoxylin und eosin staining of the ap-
pendix carcinoma. The mucinous lakes constitute more 
than 50% of the tumor mass which is a criterion for the 
mucinous type of the appendiceal carcinoma. 
 
 
Because of the young age of the patient heredi-
tary cancer syndrome was considered, although the 
family tumor history was negative for gastrointestinal 
tumors or other malignancies.  
Immunhistochemical examination showed a lack 
of expression of the two mismatch repair genes MLH1 
(figure  2)  and  MSH2  (figure  3)  possibly  associated 
with hereditary non-polyposis colon cancer syndrome 
(HNPCC or Lynch syndrome). Analysis of microsat-
ellite  instability  (MSI)  showed  high  grade  MSI 
(MSI-H) testing the markers BAT25 (stable), BAT 26 
(stable),  D2S123  (instable),  D5S346  (instable)  and 
D17S250  (instable)  (figure  4).  No  mutation  in  the 
MLH1-  and  MSH2-genes  was  detected  by  gene  se-
quencing. In addition, the tumor sample was negative 
for B-Raf mutation or evidence of DNA hypermeth-
ylation.  
Due to the histopathological classification inten-
sified  adjuvant  chemotherapy  according  to  the 
FOLFOX 4 scheme was started five weeks after sur-
gery. Currently after 24 month of follow up the pa-
tient is without detectable tumor recurrence, as shown 
by  abdominal  MR  imaging,  colonoscopy  and  ultra-
sound examination. 
 
 
 
Figure  2:  Immunhistochemical  staining  of  the  tumor. 
The blue colored cores as a sign of loss of expression of 
MLH1. The red colored cores show normal expression of 
MLH1. 
 
 
 
Figure  3:  Immunhistochemical  staining  of  the  tumor. 
The blue colored cores as a sign of loss of expression of 
MSH2. The red colored core in the center shows normal 
expression of MSH2. 
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Figure 4: PCR amplification of the repetitive DNA sequences D2S123 (A), D5S346 (B) and D17S250 (C). The upper 
sequences show the traces of the reference-DNA gained from peripheral blood. The lower sequences show the traces 
of the tumor tissue. Differences are marked by red arrows.  
 
Discussion  
Primary  adenocarcinoma  of  the  appendix  is  a 
rare neoplasm detected in less than 0.5 % of all neo-
plasms of gastrointestinal origin. Carcinomas of the 
appendix  are  usually  classified  according  to  histo-
pathological examination into four distinct subtypes 
with  varying  frequencies:  colonic  type  adenocarci-
noma,  mucinous  adenocarcinoma,  signet  ring  type 
adenocarcinoma and others. In a group of 1095 pa-
tients  with  primary  appendiceal  adenocarcinoma 
McCusker et al. (6) found 56,0% of tumors classified 
as  mucinous  appendix  carcinoma,  37,6%  were  be-
longing to the colonic and 6,4 % to the signet ring cell 
subtype.  The five year survival  rate for all  patients 
was 54.4 % and was associated with the stage of dis-
ease, the grading and the histological subtype. In a 
group of 94 patients Nitecki et al. (7) found a survival 
of 100% for patients with tumors classified as Dukes 
A,  67%  for  Dukes  B,  50%  for  Dukes  C  and  6%  for 
Dukes D carcinomas. The data presented in the liter-
ature concerning the prognosis according to the dif-
ferent  histological  subtypes  is  not  yet  conclusive. 
McCusker et al. (6) reported 5-year survival rates of 
44% for tumors with the mucinous subtype, 52% for 
the colonic subtype and 20% for the signet ring cell 
subtype. Other authors report that the mucinous his-
tology is the best prognostic factor (3, 7, 8). The gen-
eral prognosis seems to be close to that reported for 
colonic cancers (6, 7, 9).  
While simple appendectomy seems to be suffi-
cient for pT1 carcinoma of the appendix most tumors 
present  as  advanced  invasive  carcinomas  and  sec-
ondary right hemicolectomy is usually recommended 
as  the  operative  treatment  of  choice  (8).  Malignant 
infiltration of locoregional lymph nodes has to be ex-
pected in about on third of the patients and especially 
in advanced invasive tumors. Adjuvant chemothera-
py is therefore recommended in these patients with 
lymph node positive or locally advanced tumors in 
accordance with the recommendation for colon can-
cer. However, frequently carcinomas of the appendix 
show local infiltration in the surrounding peritoneum 
with  increased  risk  of  locoregional  recurrence.  For 
these  patients  with  peritoneal  tumor  infiltration  or 
peritoneal  metastasis  cytoreductive  surgery  in  com-
bination with hyperthermic chemotherapy might be 
an additional therapeutic option (10).  
Studies  investigating  the  tumorbiologic  altera-
tions of carcinomas of the appendix have so far re-
ported  classic  mutations  associated  with  sporadic 
colorectal cancer including frequent K-ras mutations, 
rare p53 protein overexpression and all tumors inves-
tigated so far were microsatellite stable (5). Therefore, 
the  mucinous  appendix  carcinoma  with  high  grade 
microsatellite instability, first described in our report, 
seems  to  represent  a  distinct  tumor  etiology  and 
might  describe  a  yet  unidentified  alteration  in  the 
DNA repair pathway with possible implications for 
chemotherapeutic  modifications  during  adjuvant 
chemotherapy. Microsatellite instabilities are found in 
tumors associated with genetic defects in DNA mis-
match repair, but they are also found in 10 – 20% of 
sporadic advanced colon carcinomas mainly caused 
by DNA hypermethylation leading to defects in DNA 
mismatch repair. Lanza et al. (11) detected a loss of 
expression  of  MLH1-  or  MSH2-genes  in  90,9%  of 
MSI-H colon carcinomas, whereas all MSI-L (low in-
stability)  and  MSS  (stable)  tumors  showed  normal 
expression of both proteins (12). There is a considera-
ble number of obviously HNPCC associated tumors 
in which a gene defect cannot be found. Genomic re-
arrangements, not detectable by PCR or sequencing, 
were found in a considerable proportion of HNPCC Journal of Cancer 2011, 2 
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families without point mutations (13). Grabowski et 
al.  (14)  found  in  their  series  of  64  patients  without 
detectable point mutations in 17% pathogenic altera-
tions in MLH1 and MSH2 genes caused by deletions. 
As our patient showed lack of protein expression of 
two mismatch repair genes, microsatellite instability 
and furthermore fulfilled the revised Bethesda Crite-
ria, a yet unidentified genetic defect, associated with 
defects in mismatch repair might represent a cofactor 
for the development of the described mucinous ap-
pendiceal carcinoma.  
However,  although  prognosis  and  survival 
seems to be better for colon cancer patients with mi-
crosatellite  instable  tumors,  microsatellite  instability 
was associated with reduced responsiveness on 5-FU 
based  adjuvant  chemotherapy  in  other  reports  (15). 
Therefore, microsatellite instability has to be consid-
ered during adjuvant chemotherapy for colorectal and 
also for rare cases of appendiceal carcinomas in pa-
tients with early onset tumors and limited response or 
tumor progression during initial 5-FU based chemo-
therapy. Although the consideration of microsatellite 
instability  is  increasing,  responsiveness  on 
5-FU-based first line chemotherapy is temporized in 
treatment of microsatellite instable colon or appendix 
carcinoma.  In  case  of  tumor  progression  or 
non-response the addition of Irinotecan, Oxaliplatin 
or  antitumor  biologicals  as  a  part  of  the  adjuvant 
chemotherapy  concept  should  be  considered  and  is 
currently investigated in clinical trials.  
Therefore, our patient received intensified adju-
vant chemotherapy according to FOLFOX-4 scheme in 
accordance to the treatment of advanced colon cancer.  
Conclusions and summary 
The patient reported shows the very rare entity 
of a mucinous adenocarcinoma of the appendix with 
high grade microsatellite instability, not yet reported 
in the literature before. Therefore, tumorbiologic al-
terations  with  so  far  unidentified  alterations  of  the 
DNA  mismatch  repair  pathway  leading  to  reduced 
expression of DNA repair proteins and microsatellite 
instability  might  be  associated  with  mucinous  ade-
nocarcinomas of the appendix. Following 5-FU based 
adjuvant  chemotherapy  relevant  variability  in  anti-
tumor response of MSI-H tumors and therefore, in-
tensified chemotherapy protocols will have to be con-
sidered in these usually young patients. 
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